Formoterol (OXIS®) Turbuhaler® as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma

Respiratory Medicine

Volumn 97, Issue 9, 2003, Pages 1067-1074

  Boonsawat, Watcha ^a,b,c,d,e   Charoenratanakul, S ^a,b,c,d,e   Pothirat, C ^a,b,c,d,e   Sawanyawisuth, K ^a,b,c,d,e   Seearamroongruang, T ^a,b,c,d,e   Bengtsson, T ^a,b,c,d,e   Brander, R ^a,b,c,d,e   Selroos, O ^a,b,c,d,e  

^a Srinagarind hospital   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Maharaj Nakorn Chiang Mai Hospital   (Thailand)

^d KHON KAEN HOSPITAL   (Thailand)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

Acute severe asthma; Formoterol Turbuhaler; Reliever medication; Salbutamol pMDI plus spacer

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; GLUCOCORTICOID; PREDNISOLONE; SALBUTAMOL; XANTHINE DERIVATIVE; ANTIASTHMATIC AGENT; ETHANOLAMINE DERIVATIVE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HUMAN; HYPESTHESIA; HYPOKALEMIA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREMOR; VERTIGO; WELLBEING; ADOLESCENT; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NEBULIZER; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ALBUTEROL; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; TREATMENT OUTCOME;

EID: 0041880644     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)00139-2     Document Type: Article

References (20)

1. Global strategy for asthma management and prevention. WHO/NHLBI workshop report. National Institutes for Health, National Heart, Lung and Blood Institute. Publication no. 02-3659, 2002.
2. Weiss EB. Status asthmaticus. In: Weiss EB, Segal MS, editors. Bronchial asthma: mechanisms and therapeutics. Boston, MA: Little, Brown, 1976. p. 875-913.
3. Stanescu DC. High doses of sympathomimetic in severe bronchial asthma. Eur Respir J 1989;2:597-8.
4. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10:2484-9.
5. Seberová E, Andersson A. Oxis® (formoterol given by Turbuhaler®) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000;94:607-11.
6. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999;13:988-92.
7. 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 1989;44:264-71.
8. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lötvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol 2000; 56:363-70.
9. Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhász G. Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir Med 2002;96:412-7.
10. Malolepszy J, Böszörményi Nagy G, Selroos O, Larsson P, Brander R. Safety of formoterol turbuhaler at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J 2001; 18:928-34.
11. Turner MO, Patel A, Ginsburg S, Fitzgerald J. Bronchodilator delivery in acute airflow obstruction. Arch Intern Med 1997; 157:1736-44.
12. 2-agonist treatment of acute asthma (Cochrane Review). Cochrane Database System Rev 2002:CD000052.
13. 2-agonists administered by dry powder inhaler can be used in acute asthma. Respir Med 1998;92:167-72.
14. Tonnesen F, Laursen LC, Evald T, Ståhl E, Ibsen TB. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest 1994;105:697-700.
15. Dejsomritrutai W, Nana A, Maranetra KN, et al. Reference spirometric values for healthy lifetime nonsmokers in Thailand. J Med Assoc Thai 2000;83:457-66.
16. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832-8.
17. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®. Respir Med 1998;92:1017-21.
18. Peters JI. Emergency treatment of asthma. Curr Opin Med 1995; 1:65-72.
19. Tötterman KJ, Huhti L, Sutinen E, et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler ® for 3 days in stable asthmatic patients. Eur Respir J 1998;12:573-9.
20. van der Woude HJ, Politiek M, Aalbers R. Formoterol provides rapid relief from acute dyspnoea following methacholine-induced bronchospasm. Eur Respir J 2002; 20 (Suppl. 38): 306s.